Please use this identifier to cite or link to this item:
Title: Skin adverse events in recently approved targeted therapies in solid malignancies
Authors: Habre, Maya
Salloum, Antoine
Habre, Samer Bassilios
Abi Chebl, Joanna
Dib, Racha
Kourie, Hampig Raphael
Affiliations: Faculty of Medicine 
Faculty of Medicine 
Keywords: Dermatologic
Monoclonal antibodies
Side effects
Targeted therapies
Tyrosine kinase inhibitors
Issue Date: 2019
Part of: Future Oncology
Volume: 15
Issue: 3
Start page: 331
End page: 343
Targeted anticancer therapies are an important weapon in the fight against cancer. Targeted therapies interfere with specific molecules necessary for tumor growth and cancer progression. They are divided mainly to either monoclonal antibodies or small molecules inhibitors. Their primary objective is to target directly and precisely the cancer cells leading to a minimal side-effects profile. The dermatologic adverse reactions of these targeted therapies is different from those seen with classical cytotoxic chemotherapy. Rashes, xerosis, hand-foot-skin reaction and mucositis are the most frequent side effects. In this paper, we aim to present a comprehensive review of the dermatologic side effects of targeted therapies including, specific side effects related to recently, approved targeted therapies.
ISSN: 14796694
DOI: 10.2217/fon-2018-0402
Type: Journal Article
Appears in Collections:Faculty of Medicine

Show full item record


checked on Apr 20, 2024

Record view(s)

checked on Apr 23, 2024

Google ScholarTM


Dimensions Altmetric

Dimensions Altmetric

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.